



GlaxoSmithKline Pharmaceuticals Limited  
GSK House, Dr. Annie Besant Road,  
Worli, Mumbai - 400 030  
Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: [www.gsk-india.com](http://www.gsk-india.com)  
Email: [askus@gsk.com](mailto:askus@gsk.com)

31<sup>st</sup> December 2025

BSE LIMITED  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED  
Exchange Plaza, 5th Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sir,

**Re: Increase in Volume**

This is in reference to your email dated today i.e. December 31, 2025, regarding clarification for significant increase in the volume of security across exchanges, in the recent past. We would like to clarify that the Company has made all the necessary disclosures pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 from time to time and has not withheld any material information/ event that in our opinion would have a bearing on the operations/ performance of the Company which include all price sensitive information, etc.

The significant increase in the volume of the Company is purely market driven. We would like to reiterate that the Company will continue to comply with the listing regulations requirements and keep the Stock Exchange informed of all price sensitive information as and when they arise.

You are requested to please take the above clarification on record and keep the members of the exchange informed.

Thanking you,

Yours faithfully  
For **GlaxoSmithKline Pharmaceuticals Limited**

*Ajay Nadkarni*

Ajay Nadkarni  
Vice President - Administration, Real Estate  
& Company Secretary

CIN: L24239MH1924PLC001151